SCHEMBL424209

SCHEMBL424209

NC(=O)c1cccc2ncc(-c3ccc(Cl)cc3)nc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 14/20 0.81
PARP2 Q9UGN5 3/20 0.73
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAP4K4 O95819 1/20 0.47
PARP3 Q9Y6F1 1/20 0.46
CASP1 P29466 1/20 0.46
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 1/20 0.43
ATR Q13535 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
RUNX1 Q01196 1/20 0.42
CBFB Q13951 1/20 0.42
DHODH Q02127 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31602072 1.00 PARP1 (0.81) PARP1PARP2NPC1RAB9ASMN1; SMN2
SCHEMBL29709959 0.89 PARP1 (1.00) PARP1PARP2NPC1RAB9ASMN1; SMN2
SCHEMBL872126 0.89 PARP1 (1.00) PARP1PARP2NPC1RAB9ASMN1; SMN2
SCHEMBL7112515 0.88 PARP1 (1.00) PARP1PARP2NPC1RAB9ADHODH
SCHEMBL7111338 0.87 PARP1 (0.80) PARP1PARP2ALDH1A1DHODH
SCHEMBL7042977 0.86 PARP1 (0.78) PARP1PARP2CASP1KMT2ADHODH
SCHEMBL7045309 0.86 PARP1 (0.78) PARP1PARP2MAP4K4ATRKDM4E
SCHEMBL7045348 0.86 PARP1 (0.69) PARP1PARP2
SCHEMBL7108289 0.84 PARP1 (1.00) PARP1PARP2CASP1ATR
SCHEMBL4777457 0.84 PARP1 (0.58) PARP1PARP2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022026-A1 METHOD OF TREATING CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2012-01-26 US claimed
EP-2387403-A1 METHOD OF TREATING CANCER Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) 2011-11-23 EP claimed
US-20110253692-A1 Electrical heater for vehicle windshields and windows SCHAUBLE RICHARD EGON 2011-10-20 US claimed
WO-2010082821-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO claimed
WO-2010082813-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO claimed
US-12186317-B2 Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase TES PHARMA S.R.L. (IT) 2025-01-07 US disclosed
US-20240366568-A1 COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY UNIV CASE WESTERN RESERVE (US) 2024-11-07 US disclosed
CN-118496217-A Inhibitors of alpha-amino-beta-carboxyhexadienoic acid semialdehyde decarboxylase TES制药有限责任公司 2024-08-16 CN disclosed
US-20240105279-A1 METHODS AND SYSTEMS EMPLOYING TARGETED NEXT GENERATION SEQUENCING FOR CLASSIFYING A TUMOR SAMPLE AS HAVING A LEVEL OF HOMOLOGOUS RECOMBINATION DEFICIENCY SIMILAR TO THAT ASSOCIATED WITH MUTATIONS IN BRCA1 OR BRCA2 GENES Genomic Testing Cooperative, LCA (US) 2024-03-28 US disclosed
US-11931339-B2 Compositions and methods for treating tissue injury CASE WESTERN RESERVE UNIVERSITY (US) 2024-03-19 US disclosed
EP-3419632-B1 NR OR NMN FOR ENHANCING LIVER REGENERATION UNIV PENNSYLVANIA (US) 2023-12-20 EP disclosed
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE TES PHARMA S.R.L. (IT) 2023-11-30 US disclosed
WO-2010082821-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO disclosed
WO-2010082813-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 WO disclosed
EP-2059802-A2 METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF Bipar Sciences, Inc. (US) 2009-05-20 EP disclosed
US-20080076778-A1 METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF BIPAR SCIENCES, INC. (US) 2008-03-27 US disclosed
WO-2008030887-A2 METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF BIPAR SCIENCES, INC. (US) 2008-03-13 WO disclosed
WO-2008015429-A2 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2008-02-07 WO disclosed
WO-2008015429-A2 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2008-02-07 WO disclosed
WO-2003007959-A1 QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076778-A1 METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF PARP3, PARP1, PARP15 PARP1 2/4885PARP2 9/4885NPC1 3612/4885
US-12186317-B2 Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase ACMSD, GLS, ALDH7A1 PARP1 1532/4885PARP2 2557/4885NPC1 2123/4885
US-11931339-B2 Compositions and methods for treating tissue injury PDK4, AK1, PDK1 PARP1 725/4885PARP2 1209/4885NPC1 4502/4885
US-20230381177-A1 INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE ACMSD, GLS, ALDH7A1 PARP1 1532/4885PARP2 2557/4885NPC1 2123/4885
US-20240366568-A1 COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY PDK4, AK1, PDK1 PARP1 725/4885PARP2 1209/4885NPC1 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.